HPV and intraepithelial neoplasia recurrent lesions of the lower genital tract: assessment of the immune system.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

HPV and intraepithelial neoplasia recurrent lesions of the lower genital tract: assessment of the immune system.

Eur J Gynaecol Oncol. 1998;19(5):466-9. Unique Identifier : AIDSLINE MED/99079618
Stentella P; Frega A; Ciccarone M; Cipriano L; Tinari A; Tzantzoglou S; Pachi A; II Clinic of Obstetrics and Gynecology, University of Rome La; Sapienza, Italy.

Abstract: OBJECTIVE: To evaluate the immune state in patients with genital relapse HPV and intraepithelial lesions of the lower genital tract. METHOD: Forty-three patients were selected. Twenty-one were affected by recurrent HPV infection either alone or combined with intraepithelial neoplasia treated by laser surgery, and 22 had been previously-treated and clinically cured without recurrence during a follow-up from 18 to 24 months. The diagnostic protocol included colposcopy with eso- and endocervical cytology histologically confirmed by directed biopsy. Afterwards patients underwent a systemic immunogenic evaluation. RESULTS: NK cell reduction was strictly related to HPV infection associated with intraepithelial lesions; B-lymphocyte reduction was percentually greater in patients affected by HPV alone; activation of R-IL2 increased in a percentage overlapping in the two groups indicating patient reaction to the virus. CONCLUSION: Our study supports the theory that immune response directed against viral antigens is one of the most important effectors in the control of HPV infections and that HPV is the cause of a systemic rather than local lesion.

Keywords: CLINICAL TRIAL JOURNAL ARTICLE Adult Antigens, CD8/ANALYSIS B-Lymphocytes/IMMUNOLOGY Cervix Dysplasia/*IMMUNOLOGY/PATHOLOGY/SURGERY CD4-CD8 Ratio Female Human Interleukin-2/ANALYSIS Killer Cells, Natural/IMMUNOLOGY Lymphocyte Count Neoplasm Recurrence, Local/DIAGNOSIS/*IMMUNOLOGY/THERAPY Neoplasms, Glandular and Epithelial/*IMMUNOLOGY/PATHOLOGY/SURGERY Papillomavirus, Human/*IMMUNOLOGY Papovaviridae Infections/DIAGNOSIS/*IMMUNOLOGY/THERAPY Prognosis Tumor Virus Infections/DIAGNOSIS/*IMMUNOLOGY/THERAPY
990530
A9950878

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .